| Heska Corporation | |||
| Ticker: | HSKA | 1825 Sharp Point Drive | |
| Exchange: | NASDAQ-National Market | Fort Collins, CO 80525 | |
| Industry: | Manufacturing (SIC Code 2836) | (970) 493-7272 | |
| Type of Shares: | Common Shares | Filing Date: | 4/24/97 | |
| U.S. Shares: | 5,000,000 | Offer Date: | 6/30/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.50 - $10.50 | |
| Primary Shares: | 5,000,000 | Offer Price: | $8.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.60 | |
| Offering Amount: | $47,500,000 | Selling: | $0.36 | |
| Expenses: | $650,000 | Reallowance: | $0.10 | |
| Shares Out After: | - |
| Manager | Tier | Phone |
| CS First Boston | Lead Manager | (212) 325-2000 |
| Merrill Lynch & Co. | Co-manager | (212) 449-4600 |
| Issuer's Law Firm: | Pillsbury Madison & Sutro |
| Bank's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Auditor: | Arthur Andersen |
| Registrar/Transfer Agent: | American Securities Transfer, Inc |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 3/31/97 | 3/31/96 | 3/31/97 | ||
| Revenue: | $9.96 | $3.06 | $0.16 | Assets: | $38.60 |
| Net Income: | -$17.98 | -$7.88 | -$2.81 | Curr Assets: | |
| EPS: | -$1.71 | -$0.67 | Liabilities: | $13.43 | |
| Prior EPS: | -$6.92 | -$2.76 | Curr Liabilities: | ||
| Cash Flow/Oper: | -$14.05 | Equity: | $25.17 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company discovers, develops, manufactures and markets companion animal health products, primarily for dogs, cats and horses. The company has six products currently on the market and over 25 products in research and development. The company also offers diagnostic laboratory services to veterinarians and operates a full scale USDA and FDA licensed facility which manufactures products for the company and other animal health companies. The company has corporate partnerships with Novartis AG, Bayer AG and Eisai Co., Ltd. And plans to expand its products and services through complementary acquisitions, licenses and collaborations. The company believes that it has the largest and most sophisticated scientific effort in the world devoted to applying biotechnology to the large and growing companion animal health market. The company is focused on providing products and services for the comprehensive management of a broad range of companion animal diseases, such as allergy, heartworm infection and flea-associated conditions. The company believes that several of its products under development may serve to expand the companion animal health market and advance the practice of veterinary medicine. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, expansion of sales and marketing activities, expansion and development of manufacturing operations, potential acquisitions, working capital and general corporate purposes. |